Multiparametric MRI Fusion-guided Biopsy for the Diagnosis of Prostate Cancer: Results of the First 100 Consecutive Patients
| Autor: | Güven Aslan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cultural Studies
lcsh:Internal medicine medicine.medical_specialty lcsh:Specialties of internal medicine detection lcsh:Medicine lcsh:RC870-923 lcsh:RC254-282 Prostate cancer lcsh:RC581-951 Biopsy Medicine prostate biopsy lcsh:RC31-1245 medicine.diagnostic_test business.industry lcsh:R Religious studies mri us fusion Multiparametric MRI prostate cancer lcsh:Diseases of the genitourinary system. Urology lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease targeted biopsy Radiology business |
| Zdroj: | Üroonkoloji Bülteni, Vol 20, Iss 1, Pp 11-14 (2021) |
| ISSN: | 2147-2270 2147-2122 |
| DOI: | 10.4274/uob.galenos.2020.1748 |
| Popis: | Objective:Our aim was to compare prostate cancer detection rates according to International Society of Urological Pathology (ISUP) grade group (GG) among magnetic resonance imaging (MRI)-targeted biopsies (TBx), systematic biopsies (SBx) and a combination of both (TBx + SBx).Materials and Methods:Between July 2018 and Nov 2020, 100 patients undergoing MRI-targeted prostate biopsy and SB were analysed retrospectively. Men with MRI-visible prostate lesions underwent both MRI-targeted (UroNav®) and systematic 12-core biopsy. The primary outcome was cancer detection according to ISUP GG. The secondary outcome were detection of cancers of GG 2 or higher.Results:The overall cancer detection rate in the study was 43%. Among these, a histopathological ISUP grade of 1 was detected in 44.2%, ISUP grade 2 in 32.5% and higher-grade groups in 23.2% of patients. MRI-TB detected 38 and SBx biopsy detected 30 of the overall study cohort. Combined biopsy led to a cancer diagnoses in 18 more men than with either method alone. Significant cancer detection was 53.4% for TBx, 39.5% for SBx, and highest 55.8% for combination TBx + SBx (p=0.038). Most of the cancers missed by SBx were clinically significant. No significant side effects were recorded. The overall cancer detection rate was 20.4%/46.6% and 90.2% for prostate imaging reporting and data system 3/4/5, respectively.Conclusion:Our results have shown that among patients with lesions visible on MRI, combined biopsy led to greater detection of all prostate cancers, providing increased detection of clinically significant tumours. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|